CXCL3



CXCL3

A1AA1S2SS2V3VV3V4VV4T5TT5E6EE6L7LL7R8RR8C9CC9Q10QQ10C11CC11L12LL12Q13QQ13T14TT14L15LL15Q16QQ16G17GG17I18II18H19HH19L20LL20K21KK21N22NN22I23II23Q24QQ24S25SS25V26VV26N27NN27V28VV28R29RR29S30SS30P31PP31G32GG32P33PP33H34HH34C35CC35A36AA36Q37QQ37T38TT38E39EE39V40VV40I41II41A42AA42T43TT43L44LL44K45KK45N46NN46G47GG47... and 26 more residue(s)...... and 26 more residue(s)

SMILES None
InChIKey None
Sequence ASVVTELRCQCLQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKACLNPASPMVQKIIEKILNKGSTN

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Ligand site mutations US28

No bioactivity data available.

CXCL3

A1AA1S2SS2V3VV3V4VV4T5TT5E6EE6L7LL7R8RR8C9CC9Q10QQ10C11CC11L12LL12Q13QQ13T14TT14L15LL15Q16QQ16G17GG17I18II18H19HH19L20LL20K21KK21N22NN22I23II23Q24QQ24S25SS25V26VV26N27NN27V28VV28R29RR29S30SS30P31PP31G32GG32P33PP33H34HH34C35CC35A36AA36Q37QQ37T38TT38E39EE39V40VV40I41II41A42AA42T43TT43L44LL44K45KK45N46NN46G47GG47... and 26 more residue(s)...... and 26 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Ligand site mutations US28

Compound is not listed as a drug.